Page 128 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Zercepac + pyrotinib versus pertuzumab in HER2+ BC
®

Availability of data 11. Loibl S, Gianni L. HER2-positive breast cancer. Lancet.
2017;389(10087):2415-2429.
Data are available from the corresponding author upon
reasonable request. doi: 10.1016/S0140-6736(16)32417-5
12. Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant
References trastuzumab, pertuzumab, and chemotherapy versus
1. Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality trastuzumab emtansine plus pertuzumab in patients with
in China, 2022. J Natl Cancer Cent. 2024;4(1):47-53. HER2-positive breast cancer (KRISTINE): A randomised,
open-label, multicentre, phase 3 trial. Lancet Oncol.
doi: 10.1016/j.jncc.2024.01.006 2018;19(1):115-126.
2. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive doi: 10.1016/S1470-2045(17)30716-7
breast cancer: Advances and future directions. Nat Rev Drug
Discov. 2023;22(2):101-126. 13. Zhu X, Ding Y, Yu Y, et al. A Phase 1 randomized study
compare the pharmacokinetics, safety and immunogenicity
doi: 10.1038/s41573-022-00579-0 of HLX02 to reference CN- and EU-sourced trastuzumab
3. Ngo D, Chen J. A clinical review of biosimilars approved in in healthy subjects. Cancer Chemother Pharmacol.
oncology. Ann Pharmacother. 2021;55(3):362-377. 2021;87(3):349-359.
doi: 10.1177/1060028020944596 doi: 10.1007/s00280-020-04196-9
4. Expert Consensus Writing Group of the Chinese Society 14. Deng W, Hu J, Li M, Yang S, Xie Z, Chen J. Trastuzumab
of Clinical Pharmacy, Chinese Medical Association. Expert biosimilar HLX02 versus reference trastuzumab in patients
consensus on clinical application and management of biosimilars with recurrent or metastatic HER2-positive breast cancer:
(First Edition). Chin Med J. 2020;100(38):2982-2989. A model-based economic evaluation for China. Expert Rev
Pharmacoecon Outcomes Res. 2022;22(7):1117-1126.
doi: 10.3760/cma.j.cn112137-20200703-02029
doi: 10.1080/14737167.2022.2107506
5. Xu B, Zhang Q, Sun T, et al. Efficacy, safety, and
immunogenicity of HLX02 compared with reference 15. Le Basle Y, Chennell P, Tokhadze N, Astier A, Sautou V.
trastuzumab in patients with recurrent or metastatic HER2- Physicochemical stability of monoclonal antibodies:
positive breast cancer: A randomized phase III equivalence A review. J Pharm Sci. 2020;109(1):169-190.
trial. BioDrugs. 2021;35(3):337-350. doi: 10.1016/j.xphs.2019.08.009
doi: 10.1007/s40259-021-00475-w 16. Ma F, Li Q, Chen S, et al. Phase I study and biomarker
6. Rodriguez G, Mancuso J, Lyman GH, et al. ASCO policy analysis of pyrotinib, a Novel irreversible Pan-ErbB receptor
statement on biosimilar and interchangeable products in tyrosine kinase inhibitor, in patients with human epidermal
oncology. JCO Oncol Pract. 2023;19(7):411-419. growth factor receptor 2-positive metastatic breast cancer.
J Clin Oncol. 2017;35(27):3105-3112.
doi: 10.1200/OP.22.00783
doi: 10.1200/JCO.2016.69.6179
7. Wu J, Jiang Z, Liu Z, et al. Neoadjuvant pyrotinib,
trastuzumab, and docetaxel for HER2-positive breast cancer 17. Xuhong J, Qi X, Tang P, et al. Neoadjuvant pyrotinib plus
(PHEDRA): A double-blind, randomized phase 3 trial. BMC trastuzumab and chemotherapy for stage I-III HER2-
Med. 2022;20(1):498. positive breast cancer: A phase II clinical trial. Oncologist.
2020;25(12):e1909-e1920.
doi: 10.1186/s12916-022-02708-3
doi: 10.1002/onco.13546
8. Watanabe H, Okada M, Kaji Y, et al. New response evaluation
criteria in solid tumours-revised RECIST guideline 18. Mao X, Lv P, Gong Y, et al. Pyrotinib-containing
(version 1.1). Gan Kagaku Ryoho. 2009;36(13):2495-2501. neoadjuvant therapy in patients with HER2-positive breast
cancer: A multicenter retrospective analysis. Front Oncol.
9. Ogston KN, Miller ID, Payne S, et al. A new histological 2022;12:855512.
grading system to assess response of breast cancers to
primary chemotherapy: Prognostic significance and doi: 10.3389/fonc.2022.855512
survival. Breast. 2003;12(5):320-327. 19. Fu C, Han H, Lin S, Xu C. A retrospective clinical study of
doi: 10.1016/s0960-9776(03)00106-1 pyrotinib in combination with trastuzumab and pertuzumab
in neoadjuvant therapy for HER-2 positive breast cancer.
10. Noone AM, Cronin KA, Altekruse SF, et al. Cancer
incidence and survival trends by subtype using data from the Chin J Clin Oncol. 2023;50(17):882-887.
surveillance epidemiology and end results program, 1992- doi: 10.12354/j.issn.1000-8179.2023.20230648
2013. Cancer Epidemiol Biomarkers Prev. 2017;26(4):632-641.
20. Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus
doi: 10.1158/1055-9965.EPI-16-0520 lapatinib plus capecitabine for the treatment of HER2-

Volume 9 Issue 3 (2025) 120 doi: 10.36922/EJMO025100044